Lantern Pharma (NASDAQ:LTRN) Issues Earnings Results, Misses Estimates By $0.03 EPS

Lantern Pharma (NASDAQ:LTRN) announced its quarterly earnings data on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03), Zacks reports.

Lantern Pharma Stock Down 2.4 %

Shares of NASDAQ:LTRN traded down $0.09 on Friday, hitting $3.63. 32,761 shares of the company traded hands, compared to its average volume of 83,882. The stock has a 50 day simple moving average of $4.26 and a 200-day simple moving average of $3.78. The company has a market cap of $39.15 million, a PE ratio of -2.04 and a beta of 1.64. Lantern Pharma has a 52 week low of $2.79 and a 52 week high of $10.06.

About Lantern Pharma

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.